A novel LRF degrader induces fetal hemoglobin expression in adult erythroblasts
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-836
Abstract: Elevating fetal hemoglobin (HbF) represents a validated therapeutic strategy for sickle cell disease (SCD) and β-thalassemia. Hydroxyurea is the only FDA-approved pharmacologic HbF inducer, but its efficacy is limited, and patient responses are variable. Emerging… read more here.
Keywords: cereblon; lrf; yu1206; degrader ... See more keywords